-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, JJ6/XrZfNOGVnvMMoRwBQhGiAkByBUG/rg6YSqxMWXApR0PwyRHnX48NIRkBZYgy uHPXVh0guXpDPfqs2CZk5w== 0001127602-10-012584.txt : 20100430 0001127602-10-012584.hdr.sgml : 20100430 20100430110916 ACCESSION NUMBER: 0001127602-10-012584 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20100428 FILED AS OF DATE: 20100430 DATE AS OF CHANGE: 20100430 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Grant Stuart CENTRAL INDEX KEY: 0001410397 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23186 FILM NUMBER: 10784755 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000882796 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 621413174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 BUSINESS PHONE: 2054444600 MAIL ADDRESS: STREET 1: 2190 PARKWAY LAKE DR CITY: BIRMINGHAM STATE: AL ZIP: 35244 4 1 form4.xml PRIMARY DOCUMENT X0303 4 2010-04-28 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001410397 Grant Stuart 2190 PARKWAY LAKE DRIVE BIRMINGHAM AL 35244- 1 SR VP & CFO Common Stock 2010-04-28 4 M 0 1563 3.26 A 10563 D Common Stock 2010-04-28 4 S 0 1563 8.26 D 9000 D Common Stock 2010-04-29 4 M 0 36990 3.26 A 45990 D Common Stock 2010-04-29 4 S 0 36990 8.31 D 9000 D Emp. Stock Option (Right to Buy) 3.26 2010-04-28 4 M 0 1563 0 D 2009-03-14 2018-03-14 Common Stock 1563 72928 D Emp. Stock Option (Right to Buy) 3.26 2010-04-29 4 M 0 36990 0 D 2009-03-14 2018-03-14 Common Stock 36990 35938 D The price in column 4 is a weighted average price. The prices actually ranged from $8.26 to $8.35. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares purchased at each price within the range for all transactions reported in this Form 4 utilizing an average weighted price. Transacted under a 10b5-1 plan that was adopted on 11/23/2009. /s/ Michael Richardson, by power of attorney 2010-04-30 -----END PRIVACY-ENHANCED MESSAGE-----